Regarded as one of the leading transformation leaders in Life Sciences, Biopharmaceuticals and Digital Healthcare, Mel Formica is globally recognized as an innovative and sought-after healthcare executive. He is a highly respected international expert with proven P&L and operational leadership experience as well as M&A advisory expertise. An innovator in developing distinctive market entry and commercial strategies for early-stage businesses, combining customer insight, vision, and creativity. Focused at the forefront of transformations in disruptive technologies, patient level data and improved quality of care.
With over 20+ years of industry experience in leadership roles at world leading companies such as at Evidera / PPD, Takeda Pharmaceuticals, Amgen Inc., IMS Health and Abbot Laboratories across Australia, US, China, Japan, Switzerland and Europe. His extensive experience spans clinical research, marketing, strategic consulting, value & access, and evidence generation which makes him a sought-after leader for C-Suites and innovative companies worldwide. As an operating advisor to private equity firms focused on healthcare, he challenges portfolio companies to think about long-term changes and strategically position new opportunities in the market.
Mel is well known in the industry as a pioneer of breakthrough concepts, global biopharmaceutical product launches and new organizational models leading to improved operating efficiency and driving business growth. With international experience to successfully drive top and bottom-line growth through building and leading complex organizations, strategic transformations, turnarounds as well as leading cross-functional teams spanning multiple geographies and complex matrix organizations.
With a vision to change the way the industry thinks, acts, and operates, Mel is the co-founder of the BCG Market Access Roundtable and the London School of Economics and Political Science (LSE) Market Access Academy. He has also been featured in numerous industry and scientific publications.
His academic and research appointments included Assistant Professor at the College of Physicians and Surgeons of Columbia University, New York, St. Luke’s-Roosevelt Hospital Center, New York and Helen Hayes Hospital, New York, US.
Mel earned his PhD (Medicine) at the University of Melbourne, Australia. He completed his post-doctoral training in the Department of Medicine at Columbia University, New York, US. In addition, he holds an Executive MBA from the Lubin School of Business, Pace University, New York, US.
